Vitalhub AI Stock Analysis
Vitalhub (VHIBF) AI Stock Analysis
Vitalhub
(Other OTC:VHIBF)
No summary available
Vitalhub (VHIBF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $443.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 18.22K
- Price to Earnings (P/E)
- 40.2
- Beta (1Y)
- 0.90
- Revenue Growth
- 30.10%
- EPS Growth
- 236.27%
- Country
- US
- Employees
- 700
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Vitalhub Business Overview & Revenue Model
Company Description
Vitalhub Corp., through its subsidiaries, provides innovative technological solutions to health and human service providers internationally, specifically catering to markets in Canada, the United States, the United Kingdom, Australia, and Western Asi...
Vitalhub Earnings Call Summary
The call was predominantly positive, supported by 14% ARR growth, 9% recurring revenue growth, a two-year-high 27% adjusted EBITDA margin, a return to net income, 69% growth in year-to-date operating cash flow, a debt-free balance sheet, successful acquisition integration, strong services backlog, and multiple AI and platform initiatives. The principal challenges were flat total revenue, lower perpetual and services revenue, a decline in gross margin, higher G&A, and uncertainty surrounding SHREWD and the NHS FDP program. Management indicated that the rest of the business remains strong and that these challenges are being offset by other growth initiatives.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
VitalHub said services revenue should tick up in Q4, with “a lot more milestones” expected to be hit than in Q3, and that Q4 “should get there”; it guides itself to 27% adjusted EBITDA margin, expects to “sustain, if not improve that number on a quarter-over-quarter basis,” and said Buddy Healthcare should reach its level in “6 months to 1 year” through “a little bit of cost reduction and revenue generation.” Ontario work is expected to continue through 2027, Novari should reach “well over the $20 million in ARR numbers,” Strata has “another $3 million to $5 million in the pipeline” over the next couple of years, and AI products could add “about $30 million, $40 million of TAM” on top of the installed base. The company believes it can recapture Rule of 40 status in 2027, with margins continuing to increase, while Attend Anywhere could “decline moderately,” although new deals may offset some of that; SHREWD represents “7%, 8% of our ARR number,” and there is “close to about $10 million or so-ish” of SHREWD revenue still out there.
Vitalhub Peers Comparison
Overall Rating
TSE:NDAT45Neutral
TSE:ADK43Neutral
TSE:CHS42.4Neutral
TSE:UDOC41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | CAD 413.27K | -16.67 | -49.83% | ― | ― | 0.00% | |
| 43Neutral | CAD 39.74M | -7.99 | 9999.00% | ― | -36.92% | 13.03% | |
| 42Neutral | CAD 10.15M | -1.47 | 64.52% | ― | 7.63% | -106.03% | |
| 41Neutral | CAD 4.32M | -1.33 | 355.56% | ― | 614.03% | 51.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VHIBF | Vitalhub Corp. | 4.61 | -1.69 | -26.85% | |
| TSE:ADK | Diagnos Inc | 0.33 | 0.05 | 17.86% | |
| TSE:NDAT | nDatalyze Corp | 0.01 | -0.00 | -33.33% | |
| TSE:CHS | Comprehensive Healthcare Systems Inc | 0.35 | -0.17 | -32.69% | |
| TSE:UDOC | Unidoc Health Corp. | 0.05 | -0.15 | -75.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
